Illumina (ILMN)
(Delayed Data from NSDQ)
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
AstraZeneca Sells Atacand's European Rights to Cheplapharm
by Zacks Equity Research
AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
Allergan's Depression Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.
Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.
Invest in 5 Mega Trends to Overcome Trade War Jitters
by Tirthankar Chakraborty
Companies involved in artificial intelligence, e-commerce, mobile payments, biotechnology and gaming are unperturbed by escalated trade war tensions. We share a few solid stocks from such spaces so that you can trade them.
Karyopharm Initiates NDA Submission Process for Selinexor
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
by Zacks Equity Research
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC
by Zacks Equity Research
The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.
J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
J&J's (JNJ) Phase III Study for Invokana Halted Earlier
by Zacks Equity Research
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina
4 Best Efficient Stocks to Add to Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
BioTime (BTX) in Focus: Stock Moves 7.3% Higher
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump
by Zacks Equity Research
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina
by Zacks Equity Research
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina
Biotech Stock Outlook: Short-Term Pricing Pain to Prevail
by Zacks Equity Research
Decline in sales of high-profile drugs, pipeline setbacks and competitive pressure are likely to adversely impact the overall performance of the biotech sector in the short term.
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
Roche's Breast Cancer Study Meets Co-Primary Endpoint
by Zacks Equity Research
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
AMGN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMGN vs. ILMN: Which Stock Is the Better Value Option?
Genomics Market Gains Momentum: 3 DNA Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Illumina, Inc. (ILMN) Outperforming Other Medical Stocks This Year?